Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 47 articles:
HTML format
Text format



Single Articles


    July 2018
  1. LOPEZ-CORTES LF, Trujillo-Rodriguez M, Baez-Palomo A, Benmarzouk-Hidalgo OJ, et al
    Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
    J Infect Dis. 2018 Jul 6. pii: 5050122. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  2. BORGIA SM, Hedskog C, Parhy B, Hyland RH, et al
    Identification of a Novel Hepatitis C Virus Genotype from Punjab, India - Expanding Classification of Hepatitis C Virus into 8 Genotypes.
    J Infect Dis. 2018 Jun 30. pii: 5047409. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. HELFRITZ FA, Bojkova D, Wanders V, Kuklinski N, et al
    Methylene Blue Treatment of Grafts during Cold Ischemia time Reduces the Risk of HCV Transmission.
    J Infect Dis. 2018 Jun 23. pii: 5043304. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. LIDOFSKY A, Holmes JA, Feeney ER, Kruger AJ, et al
    Macrophage Activation Marker Soluble CD163 is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection.
    J Infect Dis. 2018 Jun 4. pii: 5032604. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  5. COOPER CL
    Now is the Time to Quickly Eliminate Barriers along the Hepatitis C Cascade of Care.
    J Infect Dis. 2018 Mar 9. pii: 4925219. doi: 10.1093.
    PubMed     Text format    


  6. LAMOURY FMJ, Bajis S, Hajarizadeh B, Marshall AD, et al
    Evaluation of the Xpert(R) HCV Viral Load Fingerstick point-of-care assay.
    J Infect Dis. 2018 Mar 9. pii: 4925218. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. STROUVELLE VP, Braun DL, Vongrad V, Scherrer AU, et al
    No Effect of Pegylated Interferon-alpha on Total Hiv-1 DNA Load in HIV-1/HCV Coinfected Patients.
    J Infect Dis. 2018 Mar 8. pii: 4924783. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018

  8. Erratum: Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2018 Jan 27. pii: 4827080. doi: 10.1093.
    PubMed     Text format    


  9. ROLT A, Le D, Hu Z, Wang AQ, et al
    Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
    J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. SANAKA S, Kasarala GR, Tillmann HL
    A Downside to Hepatitis C Virus Cure? Vigilance Is Needed Regarding Hepatitis B Virus Reactivation, Organ Rejection, or Hepatocellular Carcinoma Progression.
    J Infect Dis. 2018 Jan 21. pii: 4770294. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. REID M, Ma Y, Scherzer R, Price JC, et al
    Contribution of liver fibrosis and microbial translocation to immune activation in HIV and HCV.
    J Infect Dis. 2018 Jan 3. pii: 4786614. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  12. PERUMALSWAMI PV, Talal AH
    Improvements in Quality of Life: A New Hepatitis C Virus Treatment Indication in Persons with Substance Use Disorders.
    J Infect Dis. 2017 Dec 26. pii: 4774700. doi: 10.1093.
    PubMed     Text format    


  13. STEPANOVA M, Thompson A, Doyle J, Younossi I, et al
    Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens.
    J Infect Dis. 2017 Dec 26. pii: 4774699. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  14. ROSENBERG BR, Freije CA, Imanaka N, Chen ST, et al
    Genetic variation at IFNL4 influences extrahepatic interferon stimulated gene expression in chronic HCV patients.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. CHAUDHURY CS, Sheehan J, Chairez C, Akoth E, et al
    No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.
    J Infect Dis. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. STEBA GS, Koekkoek SM, Vanhommerig JW, Brinkman K, et al
    DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2017
  17. HEIMER R, Binka M, Koester S, Grund JC, et al
    Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Text format     Abstract available


    April 2017
  19. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  20. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  21. HALLAGER S, Brehm Christensen P, Ladelund S, Rye Clausen M, et al
    Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population - a Danish cohort study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  22. HENGST J, Falk CS, Schlaphoff V, Deterding K, et al
    DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  23. KAN H, Imamura M, Uchida T, Hiraga N, et al
    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  24. RODRIGO C, Eltahla AA, Bull RA, Grebely J, et al
    Historical trends in the hepatitis C virus epidemics in North America and Australia.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  25. KOSTADINOVA L, Shive C, Judge C, Zebrowski E, et al
    During HCV and HCV-HIV infection elevated plasma Autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  26. MARKOWITZ M, Deren S, Cleland C, La Mar M, et al
    Chronic hepatitis C infection and the pro-inflammatory effects of injection drug use.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  27. ZEREMSKI M, Dimova RB, Pillardy J, de Jong YP, et al
    Fibrosis Progression in Patients with Chronic Hepatitis C Virus Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  28. FIERER DS
    The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression of Hepatitis C-infected Patients.
    J Infect Dis. 2016.
    PubMed     Text format    


    July 2016
  29. UCHIYAMA S, Keller N, Schlaepfer E, Grube C, et al
    Interferon alpha-Enhanced Clearance of Group A Streptococcus Despite Neutropenia.
    J Infect Dis. 2016;214:321-8.
    PubMed     Text format     Abstract available


    June 2016
  30. CHEN YI MEI SL, Burchell J, Skinner N, Millen R, et al
    Toll-like receptor expression and signalling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    March 2016
  31. MOQUEET N, Cooper C, Gill J, Hull M, et al
    Responder Interferon Lambda genotypes are associated with higher risk of liver fibrosis in HIV-Hepatitis C Virus Co-infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  32. SAKIANI S, Koh C, Heller T
    Reply to Tennant and Post.
    J Infect Dis. 2016;213:325-6.
    PubMed     Text format    


  33. MASTRO TD, Morrison CS, Hamilton CD
    Determining Hepatitis C Virus Incidence in Populations: an Important Tool for Epidemic Control.
    J Infect Dis. 2016.
    PubMed     Text format    


  34. PATEL EU, Cox AL, Mehta SH, Boon D, et al
    Hepatitis C IgG antibody avidity as a biomarker to estimate population-level incidence.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2015
  35. SWANSON S, Ma Y, Scherzer R, Huhn G, et al
    Association of HIV, HCV and Liver Fibrosis Severity with the Enhanced Liver Fibrosis Score.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  36. SVAROVSKAIA ES, Gane E, Dvory-Sobol H, Martin R, et al
    L159F and V321A Sofosbuvir Resistance Associated HCV NS5B Substitutions.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  37. OLMSTEAD AD
    Digging Deeper into Hepatitis C Virus Outbreaks.
    J Infect Dis. 2015.
    PubMed     Text format    


  38. CAMPO DS, Xia GL, Dimitrova Z, Lin Y, et al
    Accurate genetic detection of hepatitis C virus transmissions in outbreak settings.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  39. MORON-LOPEZ S, Gomez-Mora E, Salgado M, Ouchi D, et al
    Short-term treatment with IFNalpha diminishes expression of HIV-1 and reduces CD4+ T-cell activation in HIV/HCV-coinfected patients on antiretroviral therapy.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    October 2015
  40. WANDRER F, Falk C, John K, Skawran B, et al
    Interferon-mediated cytokine induction determines sustained virus control in chronic HCV infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    September 2015
  41. MARTINI H, Citro A, Martire C, D'Ettorre G, et al
    Apoptotic epitope-specific CD8+ T cells and interferon signaling intersect in chronic hepatitis C virus infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  42. SOULIER A, Poiteau L, Rosa I, Hezode C, et al
    Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis and treatment monitoring.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  43. THURSZ M, Lacombe K
    Breaking down barriers to care in Hepatitis C Virus infection.
    J Infect Dis. 2015.
    PubMed     Text format    


    August 2015
  44. TENNANT E, Post JJ
    The Production of False Positive IgM Antibodies to Hepatitis A in Autoimmune Events.
    J Infect Dis. 2015.
    PubMed     Text format    


    July 2015
  45. SPAAN M, van Oord G, Kreefft K, Hou J, et al
    Immunological analysis during IFN-free therapy for chronic HCV reveals modulation of the NK cell compartment.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  46. MCKIBBEN RA, Haberlen SA, Post WS, Brown TT, et al
    Chronic Hepatitis C Virus Infection Is Associated with Subclinical Coronary Atherosclerosis in the Multicenter AIDS Cohort Study (MACS): a Cross-Sectional Study.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  47. ZHOU N, Hernandez D, Ueland J, Yang X, et al
    NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: